Australian (ASX) Stock Market Forum

PTX - Prescient Therapeutics

Jump to new
Re: VHL - Virax Holdings

Only buy and keep VHL if you do believe in it. If you have to reply on someone's constant reassurance to keep the stock, then that is not the way to trade or invest in it. May as well just sell it and move on.
 
Re: VHL - Virax Holdings

Chart doesn't inspire much confidence, but the stock is tightly held and turnover is low. Since it's dizzy heights of 0.16 (intraday) earlier this year, there's been a steady decline:

VHL_chart_20100721.gif
"]

VHL chart 2010-07-21

From the company announcements on their South African trials, looks like late July into August is pop or flop.

Disclaimer: I hold, just topped up, today's price under 0.07. :D
Disclaimer: I also held a pile of another Aussie HIV-biotech company: Avexa (asx:AVX) which was a flop. Still hold a few, but sold some to feed the cat. So my tipping record on these matters is horrid. :banghead:

P.
 
Re: VHL - Virax Holdings

Gringotts Bank said:
Might be due for an announcement soon?

An ok proposition at 1c.
Click to expand...

I'm not aware of any upcoming announcements, but I haven't been trawling through the issued statements all that closely lately.

As may be gathered from the drop in the SP over the time of the last 2 posts, Aug 2010 was a flop. Since the then Virax has been gasping for air, not always successfully.

I don't know if there's any life in this entity or not: I watch for news, on the basis that somebody's trying to keep it afloat as a going concern. Maybe it's just their hobby.

I've seen a few ex-biotechs been gutted into shell companies, and then turned into mining ventures - SLT, BPO. I wonder if Virax isn't going to suddenly start drilling for something somewhere sometime.

As a shell, I think $0.001 or 0.002 is a better proposition than $0.01.

But as a biotech, this is real bottom of the bottom-drawer stuff.
 
Re: VHL - Virax Holdings

Ann: Merger with 4G vaccines + CR

Should be in halt but failed to lodge their half year reports so in suspension atm.
 
On December 15th, 2014, Virax Holdings Limited (VHL) changed its name and ASX code to Prescient Therapeutics Limited (PTX).
 
ASX: PTX - Undervalued Biotech Expected to Complete Three Clinical Trials in 2016 Pr

Prescient Therapeutics (“PTX,” “Prescient,” or the “Company”) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front-line chemotherapy. The Company’s novel compounds inhibit key tumor survival pathways, inhibiting cancer growth across a variety of cancers including breast, ovarian, leukemia, and multiple myeloma. PTX is currently in a Phase Ib/II trial for breast cancer (partially funded by the U.S. Department of Defense), a Phase Ib trial for ovarian cancer (partially funded by the National Cancer Institute), and expects to initiate a Phase Ib trial for Acute Myeloid Leukemia (AML) in early 2016. The Company’s science/IP comes from Yale University and Moffitt Cancer Center.
 
I can see a great deal of optimism and hope for positive outcomes, but the chart still says "SPECCIE!"
Apparently, there was a broker report in one of the daily newspapers; as a result, PTX popped up in today's Top 20 Gainers. Still, it seems worth a speculative buy as long as 10c makes the transition from resistance to holding support. I'm dipping a toe in.

PTX dly Fib 27-03-17.png
 
This is my pick for the December Stock Tipping Competition. Reason being; PTX are on track to release the three following PTX-200 results by the end of Q4 2019:

- Complete Phase 2 of PTX-200 in breast cancer
- Complete Phase 1b expanded cohort of PTX-200 AML
- Complete Phase 1b PTX-200 in ovarian cancer

Hopefully some good news on the horizon. :)
 
Cam019 said:
This is my pick for the December Stock Tipping Competition. Reason being; PTX are on track to release the three following PTX-200 results by the end of Q4 2019:

- Complete Phase 2 of PTX-200 in breast cancer
- Complete Phase 1b expanded cohort of PTX-200 AML
- Complete Phase 1b PTX-200 in ovarian cancer

Hopefully some good news on the horizon. :)
Click to expand...

Back up to 10 cents today ……

Volume is less on this thrust so a bit hard to know how many legs it might have with the 10.5 cent area generally a tough nut to crack without a gap up …

Heading in the right direction at the moment though:)
 
Steven Yatomi-Clarke, CEO of Aussie biotech Prescient Therapeutics (PTX), is holding a special investor briefing online this Wednesday evening 12 August at 7pm AEST.

Steven will discuss:
  • PTX-100 and PTX-200 trial programmes
  • Enhancements to Cell Therapy Capabilities and related intellectual property
  • PTX's next-generation CAR-T asset (OmniCAR) with the global and worldwide licence agreement it has with the University of Pennsylvania.
This is a live and interactive online session, and participants are encouraged to ask questions.

Register for this free event here: https://reachmarkets.com.au/ptx-investorbriefing/
 
I've just come across this company. They seem to have quite a few programs going for such a small oncology drug developer and it seems they are all fairly early stage - some in animal model testing and at least one phase 1 human trial for one of their treatments. I note the company is currently conducting a share purchase plan. I'm doing some reading on them. The bloke running the show is a biotech entrepreneur/banker.
 
tinhat said:
I'm doing some reading on them.
Click to expand...

Started writing this post and didnt realise you had already posted FR

Was going to ask @tinhat thoughts??

A few punters seemed a bit unhappy with the (5.5 cents) SPP

On the flip side their Cash to Market Cap ratio is one that Spec Companies usually only dream about.

I think the "new shares" start trading on Monday 31st August so the SP could get pushed either way. Tempted but might just watch it unfold for a few days.
 
A director picked up over a half million shares last Monday.
AEF a substantial holder, is doing well also. Sustainable SP growth.
I hold both. (PTX and AEF)
 
Prescient Therapeutics (ASX-PTX)
Live Investor Briefing

Thursday, 12th November 11am (AEDT)

Please join Prescient Therapeutics CEO Steven Yatomi-Clarke for a special live investor briefing.

Event Details:
Date: Thursday, 12th November
Time: 11am (AEDT)

In the session, Steven will discuss:
  • The company’s promising pipeline of cancer treatments with two targeted therapies, cell therapy enhancements and CAR-T
  • Its work in the most exciting area of cancer research “next gen” CAR-T and its OmniCAR platform
  • A strong balance sheet with $20m in the bank following oversubscribed Share Purchase Plan and Placement
This is a live and interactive session, you simply need an internet connection to participate. Don’t miss out, spots are limited – This is a FREE event.

Book your spot here: https://reachmarkets.com.au/live-investor-briefing-ptx/
 
stockhead.com.au

Chimeric IPO: What ASX stockspert Bhavdip143 likes so much about the $35m CAR T play - Stockhead

CAR T cell treatment company Chimeric Therapeutics (ASX:CHM) is understood to have easily achieved its IPO target of $35m ahead of its ASX listing Monday.
stockhead.com.au stockhead.com.au

Soon to list Chimeric Therapeutics CHM is following in the footsteps of another ASX-listed CAR T cell therapy company, Prescient Therapeutics (ASX:pTX). The company has a research partnership with the Melbourne-based Peter MacCallum Cancer Centre to produce technology that can complement CAR T treatments. The company’s CAR T cancer treatment reprograms the Chimeric Antigen Receptors (CAR) on the outside of T cells to enable them to better target and eradicate cancer cells within patients.
Click to expand...
Prescient develops personalised medical approaches to cancer including targeted and cellular therapies such as its OmniCar immune receptor platform, an advanced version of its CAR T cancer treatment. The company’s CTE programs aim to create efficacy and efficiency enhancements that are relevant to third parties in the cell therapy field, namely CAR-T, which may incorporate these into their own programs under licence. Prescient carried out a $6.5m capital raising via a share purchase plan last year to further expand its line of cancer treatments including clinical trials for its PTX 100 and 200 products, and OmniCAR platform.
Click to expand...
 
Top